Pfizer Says Key Secondary Endpoints In Phase 3 Study Of Investigational Gene Therapy Did Not Show Significant Difference Between Participants Treated With Fordadistrogene Movaparvovec And Placebo
Portfolio Pulse from Benzinga Newsdesk
Pfizer announced that key secondary endpoints in a Phase 3 study of its investigational gene therapy, Fordadistrogene Movaparvovec, did not show a significant difference between participants treated with the therapy and those given a placebo.
June 12, 2024 | 8:33 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pfizer's Phase 3 study of Fordadistrogene Movaparvovec did not meet key secondary endpoints, which could negatively impact investor sentiment and short-term stock price.
The failure to meet key secondary endpoints in a Phase 3 study is a significant setback for Pfizer's investigational gene therapy, likely leading to negative investor sentiment and a short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100